[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023.

# Download our press release (english version)

# Télécharger notre communiqué de presse (version française)